newsfilter
← Latest News
GlobeNewswire·

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027, subject to regulatory feedback Presented